Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Calcium Modification Techniques for Coronary Artery Disease
Author(s): Rodrigo Bagur , Angela McInerney , Rolf Kreutz , et al Start date: Apr 23, 2025
This webinar brings together leading experts Dr Rodrigo Bagur, Dr Angela McInerney, Dr Rolf Kreutz, Dr Sohail Khan, Dr Sophia Khattak, Dr Jonathan Hinton and Dr Peter O’Kane to explore the challenges and solutions in managing calcified coronary artery disease. The session will provide a detailed examination of coronary calcification from pathological and clinical perspectives, including… View more

Intervention
Cracking Coronary Calcium
Author(s): Jie Jun Wong , Yann Shan Keh , Yee How Lau , et al Added: 1 year ago

Intervention
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 2 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Guided or Unguided Antiplatelet Therapy: Clarifying Ambiguity
Author(s): Huai-Wen Liang , Tzung-Dau Wang Added: 5 months ago

Anticoagulation

Prevention & Chronic Conditions
ESC 25: Lifetime Benefits of Combination Therapy in HFpEF
Author(s): Muthiah Vaduganathan Added: 4 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient… View more

Heart Failure
Clinical Features and the Efficacy of Thrombolytic Therapy in de Winter
Author(s): Nirmalatiban Parthiban , Fiona Boland , Huzairi Sani Added: 9 months ago

Prevention & Chronic Conditions

MI/ACS
Characteristics and Outcomes of Patients Undergoing RotaTripsy
Author(s): Paul Jie Wen Tern , Yann Shan Keh , Yee How Lau , et al Added: 1 year ago

Intervention

Vascular Disease and Surgery
AHA 25: HFpEF as an Adipose Tissue Disorder
Author(s): Milton Packer Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 9 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure